Abstract:Objective To investigate the immune response against Hepatitis B virus (HBV) in- duced by HBsAg recombinant adenovirus (Ad-S)-transduced dendritic cells (DCs) in HBV transgenic mice (HBV-Tg),and evaluate its potential in treating chronic HBV infection.Methods DCs were generated from bone marrow cells from the HBV Tg mice.and transfected with Ad-S (DC/Ad-S) or pulsed with HBsAg protein (DC/HBsAg).HBV-Tg mice were randomly assigned to receive either DC/Ad-S (n=10) or DC/HBsAg(n=10) or pcDNA3.1(+) S plasmid (n=6),and the same im munization schedule was repeated twice at 3 week intervals.Intracellular cytokines of splenic T cells, HBsAg-specific activity of splenic cytotoxic T lymphocyte (CTL),and HBsAg and anti-HBs and HBV DNA titers in sera were detected after immunization by flow eytometry,LDH release assay, ELISA and quantitative PCR,respectively.Hepatic injury was monitored at various time points after immunization by measuring serum alanine aminotransferase (ALT) activity.Tissue samples of the liver were stained with hematoxylin and eosin for histological analysis,and the expression of hepatitis B core Ag(HBcAg) and HBsAg was assessed by immunohistochemical analysis.Results DC/Ad-S stimulated splenic Tc more efficiently to secrete IFNγthan DC/HBsAg or pcDNA3. 1 (+)-S (P＜0.05 or P＜0.01),and induced stronger splenic HBsAg-specific CTL responses than that induced by DC/HBsAg (P＜0.05 or P＜0.01 at 10:1,20:1,40:1 of E:T ratio),which were stronger than that induced by DNA vaccination (all P＜0.01 at 10:1,20:1,40:1 of E:T ratio),at 1 or 2 weeks after immunization, respectively. The CTL response elicited by DC/Ad-S was transient, rising to strongest at 1 to 2 weeks after immunization and waning gradually thereafter,but reduced more slowly than that elicited by DC/HBsAg.The suppression of serum HBsAg and HBV DNA and the reduction of expression of HBcAg and HBsAg in liver from HBV-Tg mice induced by DC/Ad-S were the strongest in all groups of immunization,and the second was that induced by DC/HBsAg from 1 to 4 weeks after immunization.The serum anti-HBs titer and ALT activity were slightly elevated,and histological analysis of the liver displayed only a very slight focal inflammatory infiltration up to 4 weeks after immunization,and the inter-group differences were not significant.Conclusions HBsAg recombinant adenovirus-transduced DCs can induce Tcl and CTL response,reduce the titer of serum HBsAg and HBV DNA,and inhibite the expression of HBcAg and HBsAg in liver in HBV-Tg mice, stronger than that induced by HBsAg-pulsed DCs or plasmid DNA.

Interleukin-2 and Interferon-Fusion Protein Expression Plasmid Enhanced Potency of HBV DNA Vaccination in HBV Transgenic Mice

TBK-1 Enhances Humoral and Cellular Immune Responses in Mice Induced by DNA Vaccination of HBV Core Gene

[Enhanced Immunogenicity of Plasmid Encoding Polyprotein Gene of Infectious Bursal Disease Virus by Co-Administration of Chicken Interleukin 2 (IL-2)].

Enhancing Cellular Immune Response to HBV M DNA Vaccine in Mice by Codelivery of Interleukin-18 Recombinant.

Immune Adjuvant Effect of Eukaryotic Expression Vector with Interleukin-2 on Hepatitis B Gene Vaccine

Immune Response Enhanced by Genes Encoding IFN-alpha 8 and T Alpha 1 Co-Inoculated with HBV DNA Vaccine

Enhancement of Cellular Immune Responses to Hepatitis B Virus Fusion Antigen DNA Vaccine in Mice by Murine IL-12

Immunization with HBsAg-Fc Fusion Protein Induces a Predominant Production of Th1 Cytokines and Reduces HBsAg Level in Transgenic Mice.

DNA-mediated Immunization to Hepatitis B Surface Antigen: Effects of a Plasmid Coexpressing Hepatitis B Surface Antigen and Interleukin-18

Non-Cytolytic Antigen Clearance in Dna-Vaccinated Mice with Electroporation

Study on the Immune Response Induced by Hbcag Gene-Modified Dendritic Cells in Hepatitis B Virus Transgenic Mice

DNA Immunization with Fusion of CTLA-4 to Hepatitis B Virus (HBV) Core Protein Enhanced Th2 Type Responses and Cleared HBV with an Accelerated Kinetic

Hbcag18-27 Epitope Fused To Hiv-Tat(49-57) Adjuvanted With Cpg Odn Induces Immunotherapeutic Effects In Transgenic Mice

Immune Response Induced by Recombinant Plasmid Expressing Double Pres2 of Hepatitis B Virus Genome in Mice

Effect of Pcdna3.1il-2/Fc As Adjuvant on HBV Pres2s DNA Vaccination

A fusion DNA vaccine encoding middle version of HBV envelope protein fused to interleukin-21 did not enhance HBV-specific immune response in mice

Interleukin 12 affects immunization of hepatitis B DNA vaccine in mice

Immune therapeutical effect induced by inoculation with recombinant plasmid encoding preS/S antigen in HBV DNA transgenic mice

Enhanced immunity and antiviral effects of an HBV DNA vaccine delivered by a DC-targeting protein.

Vaccination with A Fusion Dna Vaccine Encoding Hepatitis B Surface Antigen Fused to the Extracellular Domain of Ctla4 Enhances Hbv-Specific Immune Responses in Mice: Implication of Its Potential Use As A Therapeutic Vaccine

Enhancement of HBV Vaccine Immunogenicity with Combination of CsA and IL-2 Fusion Protein in Mice Skin Transplantation Model